ArticleAnnals of hematology2021

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1

Afsar Ali Mian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.